Effect of surgical experience on results of esophagectomy for esophageal carcinoma

Miller, J.D.; Jain, Mukesh; Gara, Christopher J. de; Morgan, Don; Urschel, John D.

doi:10.1002/(sici)1096-9098(199705)65:1<20::aid-jso4>3.3.co;2-n

Cited by 23 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ESCC is one of the most lethal malignancies in the Cancer Cell Biology world, with a 5-year survival rate of 5-25% after curative surgery. 22,23 An understanding of the molecular pathways involved in ESCC carcinogenesis would help improve diagnosis and therapy of the disease.…”

Section: Discussionmentioning

confidence: 99%

miR‐145, miR‐133a and miR‐133b: Tumor‐suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma

Kano

Seki

Kikkawa

et al. 2010

Intl Journal of Cancer

433

415

View full text Add to dashboard Cite

MicroRNAs (miRNAs), noncoding RNAs 21-25 nucleotides in length, regulate gene expression primarily at the posttranscriptional level. Growing evidence suggests that miRNAs are aberrantly expressed in many human cancers, and that they play significant roles in carcinogenesis and cancer progression. A search for miRNAs with a tumor-suppressive function in esophageal squamous cell carcinoma (ESCC) was performed using the miRNA expression signatures obtained from ESCC clinical specimens. A subset of 15 miRNAs was significantly downregulated in ESCC. A comparison of miRNA signatures from ESCC and our previous report identified 4 miRNAs that are downregulated in common (miR-145, miR-30a-3p, miR-133a and miR-133b), suggesting that these miRNAs are candidate tumor suppressors. Gain-of-function analysis revealed that 3 transfectants (miR-145, miR-133a and miR-133b) inhibit cell proliferation and cell invasion in ESCC cells. These miRNAs (miR-145, miR-133a and miR-133b), which have conserved sequences in the 3 0 UTR of FSCN1 (actin-binding protein, Fascin homolog 1), inhibited FSCN1 expression. The signal from a luciferase reporter assay was significantly decreased at 2 miR-145 target sites and 1 miR-133a/b site, suggesting both miRNAs directly regulate FSCN1. An FSCN1 loss-of-function assay found significant cell growth and invasion inhibition, implying an FSCN1 is associated with ESCC carcinogenesis. The identification of tumor-suppressive miRNAs, miR-145, miR-133a and miR-133b, directly control oncogenic FSCN1 gene. These signal pathways of ESCC could provide new insights into potential mechanisms of ESCC carcinogenesis.Human esophageal cancer occurs worldwide with a variable geographic distribution. The disease ranks eighth in order of occurrence and sixth as the leading cause of cancer mortality, affecting men more than women. 1 There are 2 main forms, each with distinct etiologic and pathologic characteristics: esophageal squamous cell carcinoma (ESCC) and adenocarcinoma. ESCC is the most frequent subtype of esophageal cancer, although the incidence of adenocarcinoma in the western world is increasing faster than other malignancies. ESCC is one of the most aggressive and lethal malignancies in eastern Asia. Because most cases of ESCC are not diagnosed until the disease is at an advanced stage, the overall 5-year survival rate is very poor.2-4 Recently, the combination of chemotherapy and radiotherapy, alone or as an adjunct to surgery, has improved the prognosis of ESCC patients. 5,6 Research over the last 20 years has identified a number of oncogenic and tumor-suppressor proteins that are associated with the induction of ESCC. 7,8 However, molecular indicators of the origin of cellular deregulation in ESCC have not been identified. Elucidation of the molecular pathways involved in ESCC carcinogenesis could lead to improvements in disease diagnosis and therapy.MicroRNAs (miRNAs) are a class of naturally occurring small (21-25 nucleotides) noncoding RNAs. Mature miRNAs play important regulatory roles in cell growth, p...

show abstract

Section: Discussionmentioning

confidence: 99%

miR‐145, miR‐133a and miR‐133b: Tumor‐suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma

Kano

Seki

Kikkawa

et al. 2010

Intl Journal of Cancer

433

415

View full text Add to dashboard Cite

show abstract

“…Twentyone 1,3,[5][6][7][9][10][11][12][13][15][16][17][18][19][20]22,[24][25][26][27] of these solely examined hospital volume, 5 4,8,14,21,28 examined both hospital and surgeon volume, and 1 examined surgeon volume in isolation. All but one 23 of the studies were retrospective, and because of the heterogeneity of the literature, no meta-analysis could be performed. Of the 25 studies examining the relationship between hospital volume and mortality, 20 reported a statistically significant benefit to large volume centres.…”

Section: Resultsmentioning

confidence: 99%

“…A total of four included studies utilized data from patients enrolled before the 1997 publication limit. 6,18,20,25 The study of Miller et al 23 was the only study reporting solely on the impact of surgeon volume and patient outcomes using data from patients enrolled before the publication limit. All studies reporting data prior to 1997 should be interpreted with caution.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review of the impact of volume of oesophagectomy on patient outcome

Lauder

Marlow

Maddern

et al. 2010

ANZ Journal of Surgery

View full text Add to dashboard Cite

Purpose: This systematic review aims to assess whether overall survival, mortality, morbidity, length of stay and cost of performing oesophagectomy are related to surgical volume. Methods: A systematic search strategy from 1997 until December 2006 was used to retrieve relevant studies. Inclusion of articles was established through application of a predetermined protocol, independent assessment by two reviewers and a final consensus decision. Results: A total of 55 studies were identified of which 27 studies, representing 68 882 patients, met the inclusion criteria. Twenty-one of these solely examined hospital volume, 5 examined both hospital and surgeon volume, and 1 examined surgeon volume in isolation. All but one of the studies were retrospective in nature, and because of the heterogeneity of the literature, no meta-analysis could be performed. Of the studies exploring the relationship between hospital volume and mortality, 20 reported a statistically significant benefit to large volume centres. Five of six included studies showed significant evidence for a reduced mortality risk with greater surgeon volume. Conclusions: Based on the evidence from these retrospective studies, oesophagectomy performed in high volume centres would appear to be associated with better outcome compared with low volume centres.

show abstract

“…Esophageal resection is not an operation for the occasional surgeon. A recent retrospective review confirmed that surgeons who perform six or more esophagectomies per year had significantly lower operative mortality [31].…”

Section: Morbidity and Mortalitymentioning

confidence: 92%

Surgical Management of Esophageal Carcinoma

Reed

1999

The Oncologist

View full text Add to dashboard Cite

Surgical management of esophageal carcinoma is reviewed. The anatomy and biology are briefly mentioned, since these factors mitigate against the success of surgery. Staging, the key to proper treatment allocation and prognosis, is discussed, including the use of endoscopic ultrasonography, positron emission tomography, and thoracoscopy/laparoscopy. Patient selection and preparation for surgery are important considerations. Surgical techniques are then discussed, as are the advantages and disadvantages of various approaches, the morbidity of surgical resection, survival, and quality‐of‐life issues. Adjuvant treatment strategies (preoperative radiation, induction chemotherapy, induction chemoradiotherapy, and postoperative treatment) are summarized.

show abstract

Effect of surgical experience on results of esophagectomy for esophageal carcinoma

Cited by 23 publications

References 0 publications

miR‐145, miR‐133a and miR‐133b: Tumor‐suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma

miR‐145, miR‐133a and miR‐133b: Tumor‐suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma

Systematic review of the impact of volume of oesophagectomy on patient outcome

Surgical Management of Esophageal Carcinoma

Contact Info

Product

Resources

About